logo
  

Myriad Announces Divestiture Of Myriad MyPath Melanoma - Quick Facts

Myriad Genetics, Inc. (MYGN) has agreed to sell the Myriad myPath Melanoma, LLC, Laboratory, to Castle Biosciences for $32.5 million in cash. myPath Melanoma, LLC, Laboratory is the laboratory that offers the myPath Melanoma test. Myriad expects the transaction to close in its fiscal second quarter.

Paul Diaz, president and CEO of Myriad Genetics, said: "The divestiture of Myriad myPath Melanoma will allow Myriad to focus on it's core businesses in Women's Health, Oncology, and Mental Health and provide growth capital for future investment."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Flavor maker McCormick & Co., Inc. is recalling certain McCormick and Frank's brand seasoning products citing possible salmonella risk, the U.S. Food and Drug Administration said. The recall involves McCormick Perfect Pinch Italian Seasoning, McCormick Culinary Italian Seasoning and Frank's RedHot Buffalo Ranch Seasoning. Drug major Pfizer Inc. raised Wednesday its outlook for fiscal 2021 earnings and revenues following strong second quarter results that exceeded market estimates. According to the company, the upward revision in full-year outlook, for the second quarter in a row, reflects its updated expectations for contributions to 2021 performance from both BNT162b2, the Pfizer-BioNTech SE COVID-19 vaccine. While reporting financial results for the second quarter on Wednesday, biopharmaceutical company Bristol-Myers Squibb Co. (BMY) reaffirmed its adjusted earnings and revenue growth guidance for the full-year 2021. For fiscal 2021, the company now projects earnings in a range of $3.18 to $3.38 per share,...
Follow RTT